title: Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms.
abstract: The effect of statin therapy on plasma adiponectin levels has not been conclusively studied. Therefore, we aimed to evaluate this effect through a systematic review and meta-analysis of available randomized controlled trials (RCTs).
  
  
  
  Quantitative data synthesis was performed using a random-effects model with weighted mean difference (WMD) and 95% confidence interval (CI) as summary statistics.
  
  
  
  In 30 studies (43 study arms) with 2953 participants, a significant increase in plasma adiponectin levels was observed after statin therapy (WMD: 0.57 μg/mL, 95% CI: 0.18, 0.95, p = 0.004). In subgroup analysis, atorvastatin, simvastatin, rosuvastatin, pravastatin and pitavastatin were found to change plasma adiponectin concentrations by 0.70 μg/mL (95% CI: -0.26, 1.65), 0.50 μg/mL (95% CI: -0.44, 1.45), -0.70 μg/mL (95% CI: -1.08, -0.33), 0.62 μg/mL (95% CI: -0.12, 1.35), and 0.51 μg/mL (95% CI: 0.30, 0.72), respectively. With respect to duration of treatment, there was a significant increase in the subset of trials lasting ≥12 weeks (WMD: 0.88 μg/mL, 95% CI: 0.19, 1.57, p = 0.012) but not in the subset of <12 weeks of duration (WMD: 0.18 μg/mL, 95% CI: -0.23, 0.58, p = 0.390). Random-effects meta-regression suggested a significant association between statin-induced elevation of plasma adiponectin and changes in plasma low density lipoprotein cholesterol levels (slope: 0.04; 95% CI: 0.01, 0.06; p = 0.002).
  
  
  
  The meta-analysis showed a significant increase in plasma adiponectin levels following statin therapy. Although statins are known to increase the risk for new onset diabetes mellitus, our data might suggest that the mechanism for this is unlikely to be due to a reduction in adiponectin expression.
authors: Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland.
authors: Piotr
authors: P
authors: Chruściel
authors: Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Research Centre, Royal Perth Hospital, School of Medicine and Pharmacology, University of Western Australia, Perth, Australia.
authors: Amirhossein
authors: A
authors: Sahebkar
authors: Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland; Healthy Aging Research Centre (HARC), Lodz, Poland.
authors: Magdalena
authors: M
authors: Rembek-Wieliczko
authors: Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Functional Sciences, Discipline of Pathophysiology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
authors: Maria-Corina
authors: MC
authors: Serban
authors: Department of Functional Sciences, Discipline of Public Health, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
authors: Sorin
authors: S
authors: Ursoniu
authors: Department of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London (UCL), London, UK.
authors: Dimitri P
authors: DP
authors: Mikhailidis
authors: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA.
authors: Steven R
authors: SR
authors: Jones
authors: Institute for Cardiovascular Medicine Timisoara, Cardiology Department, University of Medicine and Pharmacy "Victor Babes", Timisoara, Romania.
authors: Svetlana
authors: S
authors: Mosteoru
authors: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA.
authors: Michael J
authors: MJ
authors: Blaha
authors: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA.
authors: Seth S
authors: SS
authors: Martin
authors: Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland; Healthy Aging Research Centre (HARC), Lodz, Poland.
authors: Jacek
authors: J
authors: Rysz
authors: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MD, USA; Preventive Cardiology, CGH Medical Center, Sterling, IL, USA.
authors: Peter P
authors: PP
authors: Toth
authors: University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK.
authors: Gregory Y H
authors: GY
authors: Lip
authors: Duke Clinical Research Institute, Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
authors: Michael J
authors: MJ
authors: Pencina
authors: Department of Primary Care and Public Health, School of Public Health, Imperial College London, UK.
authors: Kausik K
authors: KK
authors: Ray
authors: Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Poland; Healthy Aging Research Centre (HARC), Lodz, Poland. Electronic address: maciejbanach@aol.co.uk.
authors: Maciej
authors: M
authors: Banach
mesh_terms: D052242:Adiponectin / Q000097:blood*; D000328:Adult; D000368:Aged; D000069059:Atorvastatin / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000097:blood; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017035:Pravastatin / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012044:Regression Analysis; D000068718:Rosuvastatin Calcium / Q000627:therapeutic use; D019821:Simvastatin / Q000627:therapeutic use
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011804:Quinolines; D000068718:Rosuvastatin Calcium; D000069059:Atorvastatin; D019821:Simvastatin; D017035:Pravastatin; C108475:pitavastatin
keywords: Adiponectin; Hydroxymethylglutaryl-CoA reductase inhibitors; Meta-analysis; Statins